Listen to the latest hemonc news from international experts
Moving forward in MPN: timing driver mutations and novel therapies from ASH 2020
Myeloproliferative neoplasms (MPNs) are a heterogeneous group of rare myeloid neoplasms characterized by the abnormal proliferation of hematopoietic stem cells within one or more terminal myeloid lineages. Recent advances in the field have drastically improved our understanding of the pathophysiology of MPNs, which have expanded the scope for potential novel therapies.
In this podcast, we are joined by Jyoti Nangalia, MBBChir, of Wellcome Sanger Institute, UK, Srdan Verstovsek, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, and Cem Akin, MD, of the University of Michigan, Ann Arbor, MI, to discuss pioneering data surrounding MPN pathogenesis and novel therapies presented at this year’s virtual American Society of Hematology (ASH) Annual Meeting and Exposition.
Date: 11th January 2021